MISSION appoints new CEO
This article was originally published in Scrip
Cambridge, UK-based MISSION Therapeutics, a company focused on the discovery and development of modulators of the deubiquitylating enzyme family for the treatment of cancer and other diseases, has named Dr Anker Lundemose CEO. Dr Lundemose was most recently CEO of Norwegian vaccine company Bionor Pharma.
You may also be interested in...
It is time for In Vivo's 13th annual Deals of the Year contest. We've selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A – and you get to pick the winners.
Derived from Biomedtracker, the Deal-Making column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in October 2020. Data provided by Biomedtracker.
An interactive look at recent executive-level company changes and promotions in the biopharma, medical device and diagnostics industries.